Introduction:
Essential thrombocythemia (ET) is a form of myeloproliferative neoplasms characterized by markedly increased mature megakaryocytes in the bone marrow and sustained thrombocytosis of peripheral blood.1, 2 Patients with ET, especially those with mutations in the gene encoding Janus kinase 2 (JAK2 ), may experience thrombohemorrhagic complications due to multifactorial etiologies.3-6 Anagrelide is a non-leukemogenic cytoreductive drug used for the treatment of ET in patients with a long life-expectancy; however, it is associated with the incidence of various cardiovascular side effects (5%–30%).7-9 Here, we present an 18-year-old boy with ET who developed ST-segment elevation myocardial infarction (STEMI) occurring after anagrelide initiation.